Archive · 20 Nov 2025
SeQuent-Viyash Merger Approved by NCLT
Two big companies, SeQuent Scientific and Viyash Lifesciences, have been allowed to join together by a special court.
This will make them the biggest company in India that takes care of animal health.
They will work on medicines for pets and other animals, and also make medicines for other companies.
The new company will be very strong and have a lot of money.
SeQuent Scientific and Viyash Lifesciences received NCLT approval for merger
Merger creates India's largest animal health enterprise
Merged entity to have ₹1,650 crore revenue and ₹320 crore EBITDA in H1 FY2026
Combined company to focus on pet health, bone & joint disease, dermatitis, diabetes, cardiology, and oncology
Merger to strengthen CDMO business and accelerate growth
- Who
- SeQuent Scientific Ltd. and Viyash Lifesciences Pvt. Ltd.
- What
- Received NCLT approval for merger
- When
- Recently
- Where
- India
- Why
- To create India's largest animal health enterprise
Proponents of the Merger
Potential Opponents
Growth Opportunities
Proponents of the Merger
Merger will accelerate growth in animal health market
Potential Opponents
Potential concerns about market dominance and pricing power
Financial Resilience
Proponents of the Merger
Merger provides financial resilience and stability
Potential Opponents
Potential challenges in integrating operations and maintaining profitability
- Revenue (H1 FY2026)
- ₹1,650 crore
- EBITDA (H1 FY2026)
- ₹320 crore
- Net Debt to EBITDA Ratio
- 0.7 times
- Focus Areas
- Pet health, bone & joint disease, dermatitis, diabetes, cardiology, oncology
- Stock Performance
- SeQuent Scientific shares down marginally at ₹250
